Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?
09:45am, Sunday, 16'th Feb 2025
It's only mid-February, but as of this writing biotech company Axsome Therapeutics (AXSM -0.40%) is up by 55% year to date. Substantial stock-market gains over short periods aren't that rare in the in
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
05:20pm, Tuesday, 11'th Feb 2025
Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's Auvel
Why Axsome Therapeutics Stock Is Soaring Today
11:39am, Tuesday, 11'th Feb 2025
Shares of Axsome Therapeutics (AXSM 4.36%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m.
Earnings Preview: Axsome Therapeutics (AXSM) Q4 Earnings Expected to Decline
11:06am, Tuesday, 11'th Feb 2025
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva
08:41am, Tuesday, 11'th Feb 2025
AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038.
Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?
04:36am, Tuesday, 11'th Feb 2025
Axsome (AXSM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
Why Axsome Therapeutics Stock Is Skyrocketing Today
02:45pm, Monday, 10'th Feb 2025
Shares of Axsome Therapeutics (AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m.
On Monday, Axsome Therapeutics, Inc. AXSM signed a settlement agreement with Teva Pharmaceuticals Inc TEVA.
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
11:56am, Friday, 31'st Jan 2025
The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
07:00am, Friday, 31'st Jan 2025
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will hos
US FDA approves Axsome Therapeutics' migraine drug
03:55pm, Thursday, 30'th Jan 2025
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
A single oral dose of SYMBRAVO provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours
Axsome Shares Rise 19% in a Month: What's Driving the Rally?
11:36am, Friday, 24'th Jan 2025
AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while Sunosi diversifies its business.
Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last?
10:06am, Tuesday, 14'th Jan 2025
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results
09:15am, Tuesday, 31'st Dec 2024
Axsome Therapeutics shows strong revenue growth from Auvelity and Sunosi, with promising late-stage pipeline drugs for migraine, fibromyalgia, and narcolepsy. Late-stage pipeline milestones include AX
